{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Leiomyosarcoma&page=2", "query": { "condition": "Uterine Leiomyosarcoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Leiomyosarcoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T04:14:59.172Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00897442", "title": "Collecting Tumor Samples From Patients With Gynecological Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Borderline Ovarian Clear Cell Tumor", "Borderline Ovarian Serous Tumor", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Small Cell Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Childhood Embryonal Rhabdomyosarcoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Endometrioid Stromal Sarcoma", "Gestational Trophoblastic Tumor", "Malignant Mesothelioma", "Malignant Ovarian Epithelial Tumor", "Melanoma", "Neoplasm of Uncertain Malignant Potential", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Paget Disease of the Vulva", "Recurrent Cervical Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Cervical Cancer", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage III Cervical Cancer", "Stage III Uterine Corpus Cancer", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IV Uterine Corpus Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Uterine Corpus Cancer", "Uterine Corpus Leiomyosarcoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 275, "start_date": "1992-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 187, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897442" }, { "nct_id": "NCT07467772", "title": "Ph 2 Elacestrant in ER Positive Uterine Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Sarcoma", "Uterine Leiomyosarcoma", "Endometrial Stromal Sarcoma", "ESS", "Perivascular Epithelioid Cell Tumors", "Uterine Adenosarcoma", "Uterine PEComa", "Estrogen Receptor Positive Tumor", "uLMS" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2026-04-15", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07467772" }, { "nct_id": "NCT01533207", "title": "Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Uterine Sarcoma AJCC v7", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2012-06-04", "completion_date": "2019-02-09", "has_results": true, "last_update_posted_date": "2020-04-28", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 608, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533207" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT07076186", "title": "Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2025-10-02", "completion_date": "2029-12-02", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07076186" }, { "nct_id": "NCT02601209", "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Sarcoma", "Metastatic Leiomyosarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Myxofibrosarcoma", "Recurrent Leiomyosarcoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Synovial Sarcoma", "Recurrent Undifferentiated Pleomorphic Sarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Leiomyosarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2015-11-30", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 460, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601209" }, { "nct_id": "NCT05649956", "title": "Letrozole in Uterine Leiomyosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-07-17", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 25, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Fort Lauderdale, Florida + 18 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05649956" }, { "nct_id": "NCT00087191", "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Fallopian Tube Cancer", "Gastrointestinal Stromal Tumor", "Localized Extrahepatic Bile Duct Cancer", "Localized Gallbladder Cancer", "Localized Gastrointestinal Carcinoid Tumor", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Primary Peritoneal Cavity Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Colon Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Small Intestine Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage 0 Non-small Cell Lung Cancer", "Stage I Adult Soft Tissue Sarcoma", "Stage I Colon Cancer", "Stage I Gastric Cancer", "Stage I Non-small Cell Lung Cancer", "Stage I Ovarian Epithelial Cancer", "Stage I Ovarian Germ Cell Tumor", "Stage I Pancreatic Cancer", "Stage I Rectal Cancer", "Stage I Uterine Sarcoma", "Stage II Adult Soft Tissue Sarcoma", "Stage II Colon Cancer", "Stage II Gastric Cancer", "Stage II Non-small Cell Lung Cancer", "Stage II Ovarian Epithelial Cancer", "Stage II Ovarian Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage II Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Uterine Sarcoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "motexafin lutetium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087191" }, { "nct_id": "NCT01958580", "title": "Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IA Uterine Sarcoma", "Stage IB Uterine Sarcoma", "Stage IC Uterine Sarcoma", "Stage IIA Uterine Sarcoma", "Stage IIB Uterine Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-09-17", "completion_date": "2017-02-24", "has_results": true, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01958580" }, { "nct_id": "NCT00101127", "title": "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-05-22T04:14:59.172Z", "location_count": 60, "location_summary": "Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 47 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101127" } ] }